LAVA Therapeutics NV（LVTX）股票分析

$1.740

-0.067 (-3.87%)收盤時

Loading chart…

High: 1.820
Open: 1.810
VWAP: 1.73
Vol: 285.52K
Mkt Cap: 49.43M
Low: 1.620
Amount: 493.00K
EV/EBITDA, TTM: 0.00

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

www.lavatherapeutics.com

估值指標

The current forward P/E ratio for LAVA Therapeutics NV (LVTX) is -0.93, compared to its 5-year average forward P/E of -1.72.

Forward P/E

Fair

5Y Average P/E

-1.72

Current P/E

-0.93

高估

-0.83

低估

-2.61

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.05

Current EV/EBITDA

0.00

高估

0.42

低估

-0.31

Forward P/S

Fair

5Y Average P/S

50.95

Current P/S

0.00

高估

175.07

低估

-73.17

事件時間軸

2025-11-21 (ET)

07:47:25

Xoma Completes Acquisition of Lava Therapeutics

2025-11-13 (ET)

07:41:40

Lava Therapeutics plans to withdraw from Nasdaq listing

2025-10-17 (ET)

11:46:40

Xoma and Lava Therapeutics Reveal Changes to Purchase Agreement

2025-10-02 (ET)

16:49:01

Xoma expands its proposal to purchase Lava Therapeutics

2025-08-13 (ET)

16:58:15

Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year

Show More Events

資訊

LVTX FAQ — answered by Alphio AI

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer. It operates in the Healthcare sector.

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。